The principal obstacle for anti-VISTA antibodies has been on-target/off-tumor binding to myeloid cells in the blood, resulting in high potential for CRS, whereas for targeting CTLA-4, the issue lies in disrupting the balance of Treg function and inducing autoimmune syndromes. The gene discussed is VSIR; the disease is neoplasm.